PFIZER INC - Approval.

PR Newswire UK Disclose, July, 2006

 
  European Commission Grants Conditional Marketing Authorization to Pfizer's 
                                  Sutent(R) 
 
    NEW YORK, July 27 -- Pfizer Inc said today that Sutent(R) 
(sunitinib malate) has received European conditional marketing authorization 
for advanced and/or metastatic renal cell carcinoma (mRCC), a type of advanced 
kidney cancer, after failure of interferon alfa and interleukin-2 therapies. 
    Sutent was given conditional approval for unresectable and/or metastatic 
malignant gastrointestinal stromal tumor (GIST) after failure of the imatinib 
mesylate treatment due to resistance or intolerance.  The efficacy is based on 
time to tumor progression and an increase in survival in GIST and an objective 
response rate for mRCC.  The mRCC approval is...

            
        
    
    	    
                
                
	

		

					 
            Read the rest of this article with a Free Trial at HighBeam Research.
        				
 

    		            
	
                Premium Content Partnership | 
                	HighBeam Research provides an in-depth online archive library of reference works.